Autologous– tag –
-
Thermo Fisher Scientific Unveils Semi-Automated, Closed-Loop Workflow for Autologous CAR T Cell Manufacturing: A Leap in Consistency and Safety
Thermo Fisher Scientific USA Overview Thermo Fisher Scientific has introduced a new digitally compatible, semi-automated, closed, and GMP-compliant workflow platform designed to streamline autologous CAR T cell manufacturing. Integrating... -
Kincell Bio Inaugurates and Expands State-of-the-Art GMP Cell Therapy Manufacturing Facilities in Gainesville and Research Triangle Park
Kincell Bio USA Overview Kincell Bio has opened and expanded GMP cell therapy manufacturing facilities in Gainesville, Florida, and Research Triangle Park, North Carolina, designed to support both autologous and allogeneic cell therapies... -
FUJIFILM Cellular Dynamics Opens iPSC Manufacturing Facility, Made Scientific & Pluristyx Announce iPSC Partnership Expansion
openPR.com USA Overview According to openPR.com, FUJIFILM Cellular Dynamics opened a new iPSC development and manufacturing facility in Madison in May 2026, significantly expanding its induced pluripotent stem cell production capacity. F... -
Kincell Bio Strengthens GMP Manufacturing for Autologous & Allogeneic Cell Therapies Across Diverse Modalities from US Two Sites
Kincell Bio USA Overview Kincell Bio announced enhanced GMP manufacturing services for both autologous and allogeneic cell therapy programs, leveraging two advanced facilities in Gainesville, Florida, and Research Triangle Park, North Ca... -
Chivanta Analysis: Allogeneic CAR-T Surpasses Autologous in Scalable Manufacturing and Immediate Availability, Spotlighting Fate Therapeutics’ iPSC Platform
Chivanta USA Overview Chivanta's analysis indicates allogeneic CAR-T therapies hold significant advantages over autologous CAR-T, particularly in scalable manufacturing, immediate availability, and product consistency. Companies like All... -
Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages
Drug Discovery News USA Overview Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV)... -
Market Report: US Autologous CAR-T Cell Therapy Process Optimization Market Driven by Efficiency & Cost Reduction Needs
Intel Market Research USA Overview This article summarizes the "United States Autologous CART Cell Therapy Process Optimization Market Outlook 2026-2034" report. The US autologous CAR-T cell therapy process optimization market is driven ... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th... -
Cartherics to File IND for Ovarian Cancer iPSC-Derived NK Cell Therapy CTH-401 After Asia Pacific Award
Cartherics Pty Ltd Australia Overview Australian biotech Cartherics Pty Ltd was recognized as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026. Leveraging its proprietary g... -
Gene-Edited iPSC-Derived CAR-T/NK Therapies Target Allogeneic Rejection for Off-the-Shelf Cancer Immunotherapy
MDPI Switzerland Overview Allogeneic T cell therapies represent a scalable, off-the-shelf alternative to autologous approaches, promising to overcome significant logistical and manufacturing limitations. The review highlights iPSC-derive...
